• Potentially transformative quarter ahead with results of two major efficacy trials expected in June 2026 (aGvHD) and May 2026 (osteoarthritis)
• Stronger sector backdrop with increased regulatory approvals for MSC and iPSC-derived therapies
• Cash balance of $1.6 million at end of quarter, with a capital raising pending

Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, has provided its Quarterly Activity Report for the three-month period ended 31 March 2026. The company is heading into a potentially transformative quarter, with the results of two major efficacy trials expected in June 2026 (Phase 2 aGvHD trial) and May 2026 (Phase 3 osteoarthritis trial). The regulatory, clinical and commercial proof points for MSC and iPSC-derived cell therapies have also materially improved, with a growing number of approved products and the first-ever approvals of iPSC-derived regenerative medicines in Japan in early 2026. Cynata closed the quarter with a cash balance of $1.6 million and has entered a trading halt pending an announcement regarding a capital raising. The company has also continued to strengthen its intellectual property portfolio and engage with the investment community, scientific stakeholders and prospective partners.

Cynata has not provided any high-importance, price-sensitive forward-looking financial metrics in this announcement.

The clinical readouts ahead represent the most important test of the Cymerus platform to date. Positive outcomes could lead to clinical, regulatory and commercial validation of the platform, and define the next stage of Cynata's development: regulatory progression across both lead indications, partnering discussions supported by pivotal data, and the potential to expand the Cymerus application set into additional indications.